# Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)

> **NCT02535364** · PHASE2 · TERMINATED · sponsor: **Juno Therapeutics, a Subsidiary of Celgene** · enrollment: 82 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** JCAR015 (CD19-targeted CAR T cells)

## Key facts

- **NCT ID:** NCT02535364
- **Lead sponsor:** Juno Therapeutics, a Subsidiary of Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08-21
- **Primary completion:** 2017-04-24
- **Final completion:** 2017-09-01
- **Target enrollment:** 82 (ACTUAL)
- **Why stopped:** Safety reasons
- **Last updated:** 2020-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02535364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02535364, "Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02535364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*